MSU
SLXP

Maple Securities USA’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Maple Securities USA’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,498
Closed -$390K – 296
2014
Q3 		$390K Buy
+2,498
New +$362K 0.04% 162

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Maple Securities USA's SLXP Position: Q4 2014 in Review

Maple Securities USA sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 2,498 shares — an estimated $390K sold.

Maple Securities USA first reported a position in SLXP in Q3 2014 and held it in 1 quarter. The position peaked at $390K in Q3 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • Maple Securities USA reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • Maple Securities USA sold 2,498 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $390K.
  • Maple Securities USA first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2014 and held it in 1 quarter.
  • Maple Securities USA's SALIX PHARMACEUTICALS LTD DEL position peaked at $390K in Q3 2014.
  • 346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Maple Securities USA's 13F filing for Q4 2014, filed 11 Feb 2015.